Aytu BioPharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021, compared with fiscal 2020. Although the request metadata says “2020 Q4,” this filing is an annual report for fiscal 2021, not a quarterly filing. The company is a commercial-stage specialty pharmaceutical business with prescription and consumer-health segments.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net product revenue | $65.6 million | $27.6 million |
| Gross profit / gross margin | $29.2 million / 44.5% | $19.4 million / 70.0% |
| Operating loss | $58.9 million | $21.1 million |
| Net loss | $58.3 million | $13.6 million |
| Net cash used in operating activities | $26.0 million | $28.4 million |
| Cash, cash equivalents and restricted cash at year-end | $49.9 million | $48.3 million |
- Revenue rose 138%, principally from full-year contributions of prior acquisitions, a partial year of Neos products after its March 2021 merger, and COVID-19 test sales.
- Cost of sales increased to $36.4 million, including a $7.3 million inventory write-down, primarily related to COVID-19 test kits. Gross margin fell to 44.5% from 70.0%.
- Operating expenses were $88.1 million, including $12.8 million of intangible-asset impairments, $4.9 million of restructuring costs, and $6.0 million of intangible amortization. The Tuzistra asset impairment was $8.5 million; the Natesto impairment was $4.3 million.
- Cash used in investing activities was $2.8 million; financing activities provided $30.3 million. The company raised capital through stock offerings and ATM sales, and issued 5.5 million shares as Neos merger consideration.
- At June 30, 2021, current assets were $105.2 million and current liabilities were $109.4 million, implying negative working capital of about $4.2 million. Current ratio was approximately 0.96.
- Debt included $16.0 million under the Deerfield facility and $7.9 million under the Encina revolving facility, plus finance-lease obligations. The main facilities mature May 11, 2022; Deerfield bears 12.95% annual interest and Encina bears one-month LIBOR plus 4.50%.
- Three customers accounted for 54% of FY2021 gross revenue and 85% of year-end gross receivables. This creates customer concentration and collection exposure.
Material changes versus the prior year
- The March 19, 2021 Neos merger added the Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER ADHD products, generic Tussionex, manufacturing operations, and related debt. Neos contributed approximately $11.5 million in revenue and $8.0 million to net loss after acquisition.
- The company acquired AR101 rights for vascular Ehlers-Danlos syndrome (vEDS) in April 2021 for $1.5 million cash plus fees, with up to $67.5 million of contingent payments to Rumpus, in addition to separate license obligations.
- Natesto rights were returned to Acerus effective April 1, 2021. Acerus agreed to pay $7.5 million in 30 monthly installments and repurchase inventory at cost.
- Adzenys ER was discontinued following the Neos merger, with management citing minimal revenue and a desire to focus promotion and reduce costs.
- Fiscal 2021 revenue mix was $32.7 million for the prescription segment and $33.0 million for consumer health, compared with $17.2 million and $10.4 million, respectively, in FY2020.
Outlook, commentary, risks and contingencies
- Management’s stated priorities are growing prescription and consumer-health sales, expanding the Aytu RxConnect pharmacy network, integrating Neos, and advancing AR101. The filing provides no specific revenue, earnings, or cash-flow guidance.
- Management expected to advance AR101 toward an IND and pivotal vEDS study, targeting the first calendar quarter of 2022, subject to regulatory and development progress. Healight had early findings from a five-patient, open-label study; a 40-patient controlled study was planned for fiscal 2022. Both programs remain investigational and their results are uncertain.
- The company reported $49.9 million of cash, continuing operating losses, and expected higher costs as it integrated Neos and invested in development and growth. Management said cash on hand was sufficient for potential net cash outflows for the 12 months after filing, but also stated that additional capital may be needed and could be unavailable on acceptable terms.
- Key risks include continued losses, debt repayment and covenant requirements, potential dilution from further equity issuance, reliance on wholesalers and suppliers, competition and generic entry, reimbursement and pricing pressure, controlled-substance regulation, and COVID-19-related demand or operational disruptions.
- Potential obligations include pediatric portfolio fixed payments and milestones, Innovus contingent value rights, product-related payments, and AR101 regulatory and commercial milestones and royalties. The filing lists a $3.0 million product milestone expected in FY2022 and a possible $3.0 million Tuzistra-related payment in November 2021.
- Legal matters include opioid-related lawsuits brought by Harris and Walker Counties; the filing does not provide a clear estimate of possible loss. Lawsuits relating to the Neos merger were dismissed.
- The auditor issued an unqualified opinion on the financial statements. The company disclosed a material weakness in controls over goodwill, intangible-asset and long-lived-asset impairment accounting and said it had taken remediation steps. It also stated disclosure controls were not effective at year-end, while management concluded internal control over financial reporting was effective; investors should note this distinction.
Most important facts for investors to verify
- Whether revenue growth from the enlarged portfolio translates into improved gross margins and lower operating cash use, especially after the COVID-19 inventory write-downs.
- Cash runway, liquidity needs, and the company’s ability to repay or refinance the Deerfield and Encina facilities due in May 2022, including covenant compliance.
- Actual performance and integration costs of Neos, and whether customer and receivables concentration changes.
- Progress, funding requirements, regulatory milestones, and potential payment obligations for AR101 and Healight; neither is an approved product.
- Collection timing and accounting for Acerus’s $7.5 million Natesto payments, along with other contingent and fixed obligations.
- Remediation and sustained effectiveness of financial reporting controls, particularly impairment accounting, and the status of opioid-related litigation.